334 filings
Page 12 of 17
8-K
kth0dfbuygw
21 Apr 20
Other Events
4:10pm
EFFECT
3xf5ew ede
21 Apr 20
Notice of effectiveness
12:15am
8-K
g70rf8
21 Apr 20
Other Events
12:00am
424B5
xecahzt1pxgockf3p2w
17 Apr 20
Prospectus supplement for primary offering
12:00am
8-K
1bwcd
17 Apr 20
Entry into a Material Definitive Agreement
12:00am
POS AM
flqu7mpwne 59egt0yp4
14 Apr 20
Prospectus update (post-effective amendment)
4:58pm
8-K
lmxfmcpzs9emnzdy16l
9 Apr 20
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB INVESTOR PRESENTATION 2Q 20 V1
5:30pm
EFFECT
r7elltu1a0 xq5qr2
3 Apr 20
Notice of effectiveness
12:15am
CORRESP
k5xe7662307hf
31 Mar 20
Correspondence with SEC
12:00am
UPLOAD
gwiuuccgm475
31 Mar 20
Letter from SEC
12:00am
S-3
9xdyy
24 Mar 20
Shelf registration
4:43pm
8-K
earmezlvhfdzn0uvyszn
12 Mar 20
INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer’s Disease and NASH
4:04pm
8-K
bx648snm18473op1crgt
9 Mar 20
INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17
5:14pm
8-K
nf4wv79gbs5b1ah13nz
4 Mar 20
INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results
4:00pm
8-K
wnnfarpvqg
10 Feb 20
INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS
9:22am
8-K
bzl6avxl8
27 Jan 20
Entry into a Material Definitive Agreement
5:24pm
8-K
juwnzr0knt8aenk
13 Jan 20
Regulation FD Disclosure
8:04am
8-K
hrapruw7j4j
2 Jan 20
INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer’s Disease in Obese Individuals
4:30pm
8-K
1r96yml5qloy1w ks
17 Dec 19
Regulation FD Disclosure
4:53pm